PIK3CA and ovarian clear cell cancer: Currently, a p110alpha selective inhibitor, CYH33, is under phase 2 clinical trials (NCT05043922, jRCT2031210216), which recruits patients with clear cell ovarian carcinoma with hotspot mutations in PIK3CA (Table 1) [29].